FDA Approves First Fibromyalgia Drug in 15 Years — And It Is a Repurposed Muscle Relaxant, Not a Novel Mechanism
- FDA approved Tonmya (cyclobenzaprine HCl sublingual tablets) on August 15, 2025, for the treatment of fibromyalgia in adults — the first new FDA-approved drug for fibromyalgia since milnacipran (Savella) in 2009 and only the fourth overall
- Cyclobenzaprine is a decades-old muscle relaxant (Flexeril), but Tonmya uses a sublingual formulation that bypasses first-pass hepatic metabolism, reducing the problematic long-acting metabolite norcyclobenzaprine — the innovation is in delivery, not molecule
- Phase 3 trials (RELIEF, N=503 and RESILIENT, N=457) demonstrated significant reduction in fibromyalgia pain and improvement in sleep quality vs placebo, with a once-daily bedtime dosing schedule
- Tonmya acts on multiple receptor systems (5-HT2A serotonergic, alpha-1 adrenergic, H1 histaminergic, M1 muscarinic antagonism) — a multifunctional pharmacological profile that may explain efficacy across pain, sleep, and fatigue domains simultaneously
Fifteen years. That is how long fibromyalgia patients waited for a new FDA-approved treatment option. The gap reveals what clinical psychologists already know: fibromyalgia has been orphaned by pharmaceutical investment. The condition is common (2-4% prevalence, predominantly women), disabling, and associated with severe psychological comorbidity — yet the pharmacological pipeline has been essentially empty since 2009.
Tonmya's approval is notable not for what it introduces but for what it repurposes. Cyclobenzaprine has been prescribed off-label for fibromyalgia for decades. The problem was never efficacy — it was tolerability. Oral cyclobenzaprine produces excessive daytime sedation, dry mouth, and cognitive fog through its long-acting metabolite norcyclobenzaprine. The sublingual formulation reduces this metabolite by bypassing hepatic first-pass metabolism, preserving the therapeutic effects while reducing next-day carryover.
What this means for mental health practitioners
For psychologists treating fibromyalgia comorbid with depression/anxiety: Tonmya's multireceptor profile — particularly 5-HT2A antagonism — has theoretical relevance to mood and sleep beyond pure pain modulation. In practice, this means your patients on Tonmya may report improvements in sleep architecture and daytime functioning that create a better therapeutic window for psychological intervention. Better sleep and less fatigue = more capacity for CBT, ACT, or behavioural activation.
For the 54% overlap: Research consistently shows that 54% of fibromyalgia patients have comorbid depression and 55.5% have comorbid anxiety. A new pharmacological option that addresses pain, sleep, and fatigue simultaneously may reduce the polypharmacy burden that many of these patients carry — fewer sedating medications, potentially fewer interactions with SSRIs and SNRIs.
For access and equity: Tonmya is a brand-name drug entering a market where all three existing FDA-approved options (pregabalin, duloxetine, milnacipran) are available as generics. Pricing, insurance coverage, and prior authorization requirements will determine whether this approval reaches the patients who need it or joins the growing list of approved-but-inaccessible treatments. The Relief of Chronic Pain Act (S.3064), currently before Congress, would waive Medicare Part D deductibles and prohibit step therapy for non-opioid pain drugs — directly relevant to Tonmya's accessibility.
For the broader field: This approval may renew pharmaceutical interest in fibromyalgia and chronic pain — conditions that investors abandoned when early candidates failed. But the mechanism (a reformulated generic) also illustrates the limits of the current model: after 15 years, the best the industry produced was not a new molecule but a better delivery system for an old one.
The FDA approved its first new fibromyalgia drug in 15 years — Tonmya, a sublingual reformulation of cyclobenzaprine. The innovation is not in the molecule but in the delivery: bypassing liver metabolism to keep the therapeutic effect while reducing daytime sedation. For the 54% of fibromyalgia patients with comorbid depression, the simultaneous improvement in pain, sleep, and fatigue may create better conditions for psychological treatment.
Phase 3 trial populations may not reflect real-world fibromyalgia patients (comorbidity exclusions, controlled settings). Long-term efficacy and safety data beyond the trial period are not yet available. As a centrally-acting agent with anticholinergic properties, Tonmya has contraindication and interaction profiles that require careful evaluation, particularly in patients already on SSRIs/SNRIs. Brand-name pricing may limit access. The sublingual formulation requires specific administration technique (under tongue, no swallowing for 2 minutes) that may affect compliance.